Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) saw some unusual options trading on Wednesday. Investors bought 3,187 call options on the company. This represents an increase of approximately 407% compared to the typical volume of 629 call options.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a report on Monday. Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. TD Cowen downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. HC Wainwright reduced their price target on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Finally, Cowen lowered shares of Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.00.

Hedge Funds Weigh In On Repare Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Quinn Opportunity Partners LLC bought a new stake in Repare Therapeutics during the second quarter valued at about $56,000. Affinity Asset Advisors LLC increased its holdings in shares of Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after purchasing an additional 100,000 shares during the period. Lantern Wealth Advisors LLC acquired a new position in shares of Repare Therapeutics during the third quarter valued at about $35,000. Squarepoint Ops LLC bought a new stake in shares of Repare Therapeutics in the third quarter valued at about $115,000. Finally, Rangeley Capital LLC acquired a new stake in Repare Therapeutics during the second quarter worth about $494,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Repare Therapeutics Price Performance

Repare Therapeutics stock traded up $0.39 during trading hours on Wednesday, hitting $2.56. The company had a trading volume of 14,213,543 shares, compared to its average volume of 409,888. Repare Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $2.66. The firm’s fifty day moving average is $2.00 and its 200-day moving average is $1.74. The firm has a market capitalization of $110.15 million, a P/E ratio of -1.51 and a beta of 1.02.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to analyst estimates of $7.50 million. Analysts anticipate that Repare Therapeutics will post -2.04 earnings per share for the current year.

About Repare Therapeutics

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.